Special Issue

Staphylococcus aureus Skin and Soft Tissue Infections Pathogenesis and Therapeutic Approaches, 2nd Edition

Message from the Guest Editors

The first volume of the Special Issue "Staphylococcus" aureus Skin and Soft Tissue Infections Pathogenesis and Therapeutic Approaches" was published in the beginning of 2024. It is a successful issue with seven published papers and has encouraged us to open a second volume with the same topic. Staphylococcus aureus skin and soft tissue infections (SSTIs) represent a major threat to public health given the massive number of infections and the widespread emergence of antibiotic-resistant isolates, such as MRSA, both in the hospital and the community. Moreover, whereas many SSTIs are relatively minor and self-limiting, complicated SSTIs can be life threatening. To this end, the understanding of SSTI pathogenesis is critical to develop new strategies that can contribute not only to efficiently eradicate the bacteria from the skin but also to decrease tissue damage as well as bacterial invasion and spread to the bloodstream. As a continuation of the Special Issue, this second volume will also aim to provide new insights into the complex interaction of S. aureus with the host in the skin microenvironment and in novel therapeutic approaches.

Guest Editors

Dr. Marisa I. Gómez

Dr. Cintia González

Dr. Constanza Giai

Deadline for manuscript submissions

closed (30 April 2025)



an Open Access Journal by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



mdpi.com/si/210455

Antibiotics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

mdpi.com/journal/ antibiotics





an Open Access Journal by MDPI

Impact Factor 4.6 CiteScore 8.7 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery. use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciples are all key. Antibiotics is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon

School of Chemistry and Molecular Bioscience, University of Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)

